First Clinical Investigation of a Gene Therapy (YAP101) to Induce Cardiac Regeneration to Treat Heart Failure Passes Initial Safety Hurdle
Medley Therapeutics, Inc. (formerly YAP Therapeutics), a company developing regenerative genetic medicines and advanced biologics, today announced completion of dosing in the first cohort (n=3) of the Phase 1 SALVADOR-HF clinical trial evaluating YAP101 in patients with advanced ischemic heart failure with reduced ejection fraction (HFrEF) at The Texas Heart Institute at Baylor College of Medicine and at the St. Luke’s Medical Center (Houston). Following favorable safety findings, the study’s independent Safety Review Team recommended escalation to the next protocol-defined dose level.
